SEC digs into Pfizer's overseas profits, tax reductions
This article was originally published in Scrip
Executive Summary
Pfizer had some "splainin' to do" when the Securities & Exchange Commission (SEC) said the pharma giant's reported domestic operations pre-tax losses of $2.2 billion in the US in 2011, with international operations producing pre-tax earnings of $15 billion, didn't quite jibe with what the firm reported for domestic and international revenues, which that year were $26.9 billion and $40.5 billion, respectively.